In this episode, Nilofer S. Azad, MD, and Kanwal Raghav, MD, discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC, with topics including:
- Current use of regorafenib and TAS-102 monotherapy
- Combination therapy with regorafenib and PD-1 inhibitors
- Adding bevacizumab to TAS-102
Presenters:
Nilofer S. Azad, MD
Professor, Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland
Kanwal Raghav, MD
Associate Professor, GI Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, Texas
Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Follow along with the slideset:
https://bit.ly/3NLejWe
Link to full program:
https://bit.ly/33yrIyh
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Decera Clinical Education Oncology Podcast